Familial central precocious puberty due to DLK1 deficiency: novel genetic findings and relevance of serum DLK1 levels.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
01 Sep 2023
Historique:
received: 05 06 2023
revised: 22 07 2023
accepted: 10 08 2023
pmc-release: 13 09 2024
medline: 27 9 2023
pubmed: 13 9 2023
entrez: 13 9 2023
Statut: ppublish

Résumé

Several rare loss-of-function mutations of delta-like noncanonical notch ligand 1 (DLK1) have been described in non-syndromic children with familial central precocious puberty (CPP). We investigated genetic abnormalities of DLK1 gene in a French cohort of children with idiopathic CPP. Additionally, we explored the pattern of DLK1 serum levels in patients with CPP and in healthy children at puberty, as well as in wild-type female mice. Genomic DNA was obtained from 121 French index cases with CPP. Automated sequencing of the coding region of the DLK1 gene was performed in all cases. Serum DLK1 levels were measured by enzyme linked immunosorbent assay (ELISA) in 209 individuals, including 191 with normal pubertal development and in female mice during postnatal pubertal maturation. We identified 2 rare pathogenic DLK1 allelic variants: A stop gain variant (c.372C>A; p.Cys124X) and a start loss variant (c.2T>G; p.Met1?, or p.0) in 2 French girls with CPP. Mean serum DLK1 levels were similar between healthy children and idiopathic CPP children. In healthy individuals, DLK1 levels correlated with pubertal stage: In girls, DLK1 decreased between Tanner stages III and V, whereas in boys, DLK1 decreased between Tanner stages II and V (P = .008 and .016, respectively). Serum levels of Dlk1 also decreased in wild-type female mice. Novel loss-of-function mutations in DLK1 gene were identified in 2 French girls with CPP. Additionally, we demonstrated a pattern of dynamic changes in circulating DLK1 serum levels in humans and mice during pubertal stages, reinforcing the role of this factor in pubertal timing.

Sections du résumé

BACKGROUND BACKGROUND
Several rare loss-of-function mutations of delta-like noncanonical notch ligand 1 (DLK1) have been described in non-syndromic children with familial central precocious puberty (CPP).
OBJECTIVE OBJECTIVE
We investigated genetic abnormalities of DLK1 gene in a French cohort of children with idiopathic CPP. Additionally, we explored the pattern of DLK1 serum levels in patients with CPP and in healthy children at puberty, as well as in wild-type female mice.
PATIENTS AND METHODS METHODS
Genomic DNA was obtained from 121 French index cases with CPP. Automated sequencing of the coding region of the DLK1 gene was performed in all cases. Serum DLK1 levels were measured by enzyme linked immunosorbent assay (ELISA) in 209 individuals, including 191 with normal pubertal development and in female mice during postnatal pubertal maturation.
RESULTS RESULTS
We identified 2 rare pathogenic DLK1 allelic variants: A stop gain variant (c.372C>A; p.Cys124X) and a start loss variant (c.2T>G; p.Met1?, or p.0) in 2 French girls with CPP. Mean serum DLK1 levels were similar between healthy children and idiopathic CPP children. In healthy individuals, DLK1 levels correlated with pubertal stage: In girls, DLK1 decreased between Tanner stages III and V, whereas in boys, DLK1 decreased between Tanner stages II and V (P = .008 and .016, respectively). Serum levels of Dlk1 also decreased in wild-type female mice.
CONCLUSIONS CONCLUSIONS
Novel loss-of-function mutations in DLK1 gene were identified in 2 French girls with CPP. Additionally, we demonstrated a pattern of dynamic changes in circulating DLK1 serum levels in humans and mice during pubertal stages, reinforcing the role of this factor in pubertal timing.

Identifiants

pubmed: 37703313
pii: 7273070
doi: 10.1093/ejendo/lvad129
pmc: PMC10519858
doi:

Substances chimiques

Calcium-Binding Proteins 0
DLK1 protein, human 0
Membrane Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

422-428

Subventions

Organisme : NIH HHS
ID : R01 HD082314
Pays : United States

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflict of interest: None declared.

Références

Exp Cell Res. 2005 Feb 15;303(2):343-59
pubmed: 15652348
Int J Obes (Lond). 2008 Jul;32(7):1122-9
pubmed: 18392037
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):16088-93
pubmed: 25349437
J Clin Endocrinol Metab. 2017 May 1;102(5):1557-1567
pubmed: 28324015
Front Endocrinol (Lausanne). 2021 May 18;12:585887
pubmed: 34084149
Nat Commun. 2022 Mar 30;13(1):1831
pubmed: 35354829
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
PLoS One. 2012;7(4):e36134
pubmed: 22563444
J Endocrinol Invest. 2023 Jun;46(6):1233-1240
pubmed: 36577869
Biochim Biophys Acta. 2012 Jun;1822(6):988-95
pubmed: 22353464
Pediatr Res. 2019 Aug;86(2):195-201
pubmed: 31091532
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2112-2120
pubmed: 30462238
EBioMedicine. 2019 Aug;46:368-380
pubmed: 31383551
Alcohol. 2014 Dec;48(8):795-800
pubmed: 25449367
Curr Top Dev Biol. 2010;92:73-129
pubmed: 20816393
Sci Adv. 2019 Feb 20;5(2):eaau9425
pubmed: 30801013
Development. 2019 Feb 1;146(3):
pubmed: 30709911
Best Pract Res Clin Endocrinol Metab. 2019 Jun;33(3):101262
pubmed: 30733078
J Clin Endocrinol Metab. 2020 Oct 1;105(10):
pubmed: 32676665
Mol Genet Genomic Med. 2022 Dec;10(12):e2087
pubmed: 36353763
Eur J Hum Genet. 2021 Dec;29(12):1756-1761
pubmed: 34276055
Mol Cell Biol. 2002 Aug;22(15):5585-92
pubmed: 12101250
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034

Auteurs

Luciana Montenegro (L)

Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Hospital das Clínicas, Departamento de Clínica Médica, Disciplina de Endocrinologia e Metabologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, 05403-000, Brazil.

Carlos Seraphim (C)

Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Hospital das Clínicas, Departamento de Clínica Médica, Disciplina de Endocrinologia e Metabologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, 05403-000, Brazil.

Flávia Tinano (F)

Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Hospital das Clínicas, Departamento de Clínica Médica, Disciplina de Endocrinologia e Metabologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, 05403-000, Brazil.
Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 021115, United States.

Maiara Piovesan (M)

Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Hospital das Clínicas, Departamento de Clínica Médica, Disciplina de Endocrinologia e Metabologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, 05403-000, Brazil.

Ana P M Canton (APM)

Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Hospital das Clínicas, Departamento de Clínica Médica, Disciplina de Endocrinologia e Metabologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, 05403-000, Brazil.

Ken McElreavey (K)

Human Developmental Genetics Unit, Institute Pasteur, Paris, 75724, France.

Severine Brabant (S)

Assistance Publique Hopitaux de Paris, Department of Functional Explorations, Necker Enfants Malades Hospital, Paris-Centre University, Paris Cedex, 75015, France.

Natalia P Boris (NP)

Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 021115, United States.

Melissa Magnuson (M)

Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 021115, United States.

Rona S Carroll (RS)

Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 021115, United States.

Ursula B Kaiser (UB)

Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 021115, United States.

Jesús Argente (J)

Department of Pediatrics, Universidad Autónoma de Madrid, Madrid, 28049, Spain.
Department of Pediatrics & Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, Madrid, 28009, Spain.
Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, 28029, Spain.
IMDEA Food Institute, CEIUAM+CSIC, Madrid, 28049, Spain.

Vicente Barrios (V)

Department of Pediatrics, Universidad Autónoma de Madrid, Madrid, 28049, Spain.
Department of Pediatrics & Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, Madrid, 28009, Spain.
Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, 28029, Spain.
IMDEA Food Institute, CEIUAM+CSIC, Madrid, 28049, Spain.

Vinicius N Brito (VN)

Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Hospital das Clínicas, Departamento de Clínica Médica, Disciplina de Endocrinologia e Metabologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, 05403-000, Brazil.

Raja Brauner (R)

Pediatric Endocrinology Unit, Hôpital Fondation Adolphe de Rothschild and Université Paris Cité, Paris, 75019, France.

Ana Claudia Latronico (AC)

Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Hospital das Clínicas, Departamento de Clínica Médica, Disciplina de Endocrinologia e Metabologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, 05403-000, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH